Flex Pharma Focuses On Phase 2 Clinical Programs In Severe Neurological Diseases
January 24, 2017 at 11:03 AM EST
These randomized, controlled, blinded, cross-over studies are designed to evaluate the safety and efficacy of FLX-787 in patients who suffer from cramps and spasticity as a consequence of their disease.
